Proteins that inhibitglycoprotein (GP) IIb/IIIamediated platelet aggregation have been purified from the venom of two snake species. A small platelet aggregation inhibitor (pl.AI), multisquamatin (Mr=5,700), was purified from for contortrostatin displacement of 7E3 binding to uman and canine GPIIb-/IIIa is 27 nM and 16 nM, respectively and for multisquamatin it is 3 nM and 63 nM, respectively.
Platelets serve an important role in mediating coronary artery thrombosis and rethrombosis in the genesis of acute myocardial infarction (1). Thus inhibition of platelet aggregation may provide an effective adjunctive approach for prevention of coronary artery reocclusion after successful thrombolytic therapy. Platelet aggregation involves the interaction of the platelet membrane glycoprotein (GP) IIb/IIIa receptor with plasma fibrinogen. GPIIb/IIIa belongs to the superfamily of integrin cell surface receptors (2) .
Integrins are heterodimers composed of a and Q subunits that are noncovalently associated.
They have been shown to be involved in cell-cell and cell-substratum interactions (3). It has been shown that both the a and the fl subunits are required for fibrinogen binding (3).
Integrins serve as receptors for extracellular matrix proteins such as fibronectin, fibrinogen, vitronectin, collagen and laminin (3). Some of these interactions have been shown to be mediated via an Arg-Gly-Asp (RGD) sequence present in the matrix proteins (3). For platelet aggregation an RGD sequence present in fibrinogen is essential for the interaction with GPIIb/IIIa (3).
A number of disintegrins
or platelet aggregation inhibitors (pl.AIs) have been isolated from snake venoms (4-9).
They are small proteins, rich in disulfide bonds and contain the RGD sequence. Recently pl.AIs have been characterized with respect to the amino acid sequence around the RGD site (10). The RGD sequence is present in all known pl.AIs except barbourin, the pl.AI purified from Sisturus m. barbouri, which has a Lys-Arg-Asp (KGD) sequence instead of RGD and seems to be highly GPIIb/IIIa specific (8).
In this communication, we describe two pl.AIs, contortrostatin and multisqamatin, that have been purified from different snake venoms. Contortrostatin was purified from the venom of Agkistrodon contortrix contortrix (Southern copperhead) and multisquamatin was purified from the venom of Echis multisquamatus.
We have studied the inhibitory activity of both proteins on platelets obtained from humans and two animal species. We have also studied the ability of these pl.AIs to compete for binding sites with a monoclonal antibody (7E3) directed to GPIIb/IIIa (11).
In this report we present evidence indicating that contortrostatin and multisquamatin inhibit platelet aggregation by binding to the integrin receptor, GPIIb/IIIa. Fractions of 10 ml were collected in a Pharmacia Frac 100 fraction collector at 4'C using a flow rate of 5 ml/min. Fractions containing pl.AI activity were pooled and concentrated by ultrafiltration using an Amicon stir cell with a YM3 membrane. Purification of multisauamatin, the platelet assresation inhibitor from Echis multisquamatus venom: Multisquamatin was purified from 1 gram of Echis multisquamatus venom by a three step HPLC procedure.
MATERIALS AND METHODS

Materials
In the first step crude venom (1 g) was treated as Agkistrodon contortrix contortrix venom and applied to the HIC-HPLC column.
Elution conditions were identical to the first step employed for the purification of contortrostatin.
Pl.AI activity coeluted with platelet aggregatory activity in the HIC flow through.
Cl8 RP-HPLC was employed to separate platelet inhibitory activity from platelet aggregatory activity. Fractions from the HIC flow through were pooled and concentrated using an Amicon stir cell with a YM3 membrane and subsequently applied to a Cl8 RP-HPLC column (218TP510). Elution was achieved as follows: 10 minute isocratic at 95% solvent A and 5% solvent B; a linear gradient to 30% solvent B over 110 minutes; and a linear gradient from 30% to 100% solvent B over 30 minutes; isocratic at 100% solvent B for 30 minutes.
Fractions of 10.5 ml were collected at a flow rate of 7 ml/minute at 4OC. Active fractions were pooled, concentrated using a Savant Rotovac, and rerun on the same Cl8 RP-HPLC column.
Elution was achieved as follows: 10 minute isocratic at 95% solvent A and 5% solvent B; a linear gradient to 30% solvent B over 80 minutes; a linear gradient 42 VENOM DISINTEGRINS from 30% to 100% solvent B over 10 minutes; solvent B for 10 minutes.
The peak containing collected manually.
Vol. 73, No. 1 isocratic at 100% pl.AI activity was Assav of nlatelet assresation inhibitorv activitv: Column fractions obtained during purification were assayed for pl.AI activity using fresh human platelet rich plasma (PRP) prepared from blood obtained from human volunteers who had no medication for at least two weeks. Blood (36 ml) was drawn into 4 ml of 0.1 M citrate and centrifuged at 150 x g for 20 minutes. The supernatant, PRP, was removed and the remaining blood was centrifuged at 10,000 RPM to obtain platelet poor plasma (PPP). Platelet counts were adjusted to 250,000 platelets/+ using a Coulter counter. A Bio-Data one channel aggregometer and a Helena four channel aggregometer were used to monitor platelet aggregation.
Inhibition of ADP-induced platelet aggregation was monitored at 37OC by adding venom fractions one minute prior to the addition of ADP (lo-20 PM final concentration).
Fractions exhibiting pl.AI activity were pooled and further purified.
Rabbit and canine PRP was prepared by the same procedure and used in the studies described below.
SDS-nolvacrvlamide se1 electroDhoresis (SDS-PAGE):
A Tris-Tricine 16.5% gel was used according to the protocol of Schagger and von Jagow under reducing and nonreducing conditions (13). The gel was run using a Biorad minigel system and stained with silver (14) or Coomassie blue R250. 
Measurement of GPIIb
RESULTS
Purification of contortrostatin:
Contortrostatin was purified from Southern copperhead venom using a three step chromatographic approach: HIC-HPLC, and two steps on Cl8 RP-HPLC. For the first step of purification crude venom was disolved in a minimal volume of HIC buffer A and applied to the HIC-HPLC column. Proteins were eluted by a decreasing gradient of ammonium sulfate and were detected at 280 nm (Fig. 1 A) .
Pl.AI activity was observed in the flow through.
Fractions containing pl.AI activity were pooled and concentrated for the second step of purification.
In this step pooled fractions were applied to a Cl8 RP-HPLC column equilibrated with 0.1% TFA and 4% acetonitrile. Elution was achieved by an increasing gradient of acetonitrile (Fig. 2 A) . Contortrostatin eluted at 28% acetonitrile (66 min). For the final step of purification, fractions containing pl.AI activity were applied to the Cl8 RP-HPLC column this time equilibrated with 0.1% TFA and 16% acetonitrile. Using a shallower gradient to 24% acetonitrile (Fig. 3 A) , contortrostatin eluted as a sharp peak at 22% acetonitrile (82 min). The minor peak eluting just before contortrostatin also contained pl.AI activity and had a similar molecular weight to that of contortrostatin.
Due to the low yield this peak was not further characterized.
Yields of l-2 mg of three step purified contortrostatin were obtained per gram of crude venom.
Purification of multissuamatin:
Multisquamatin was purified from Echis multisquamatus venom by a similar chromatographic approach to that used for the purification of contortrostatin.
Crude venom was directly applied to the HIC-HPLC column under the same conditions used for Southern copperhead venom.
Elution was achieved by a decreasing gradient of ammonium sulfate (Fig. 1 B) . The major protein peak eluting in the flow through possessed platelet aggregating activity.
This peak also contains pl.AI activity but it was difficult to detect due to the coeluting platelet aggregating activity.
To confirm that the HIC flow through peak possessed pl.AI activity we applied aliquots to an analytical Cl8 RP-HPLC column (218TP54). One of the major peaks eluting from the Cl8 RP-HPLC column possessed pl.AI activity thereby indicating that the flow through peak from the HIC-HPLC column contains pl.AI activity.
Active fractions from the HIC column were pooled, concentrated, and applied to the preparative Cl8 RP-HPLC column equilibrated with 0.1% TFA and 4% acetonitrile. Elution was obtained by an increasing gradient to 80% acetonitrile (Fig.2 B) . Pl.AI activity was obtained in the major peak eluting at 14% acetonitrile (61 mins).
In order to remove minor contaminants multisquamatin was rerun on the Cl8 RP-HPLC column (Fig. 3  B) . Multisquamatin eluted at 68 min (16% acetonitrile). Yields of lo-11 mg of three step purified multisquamatin were obtained per gram of crude venom. Refer to Materials and Methods for elution conditions. Peaks containing pl.AI activity are indicated by the arrows. 
Final step of purification of contortrostatin and multisquamatin. (A) Contortrostatin was further purified by rerunning on the Cl8 RP-HPLC column but with a shallower gradient. It eluted at 82 min (22% acetonitrile) and was collected manually. Multisquamatin was further purified
by rerunning on the Cl8 column using the same gradient as in the second step. It eluted at 68 min (16% acetonitrile) and was collected manually. Refer to Materials and Methods for elution conditions. Arrows indentify peaks containing pl.AI activity.
SDS-PAGE analysis:
Reducing and nonreducing SDS-PAGE were used to assess homogeneity and to calculate molecular mass of purified pl.AIs (Fig. 4) . SDS-PAGE analysis of contortrostatin revealed that it has a molecular mass of approximately 15,000 Da under nonreducing conditions and 5,000-7,000 Da under reducing conditions, thereby suggesting that it is composed of two or three subunits.
Another possibility, although unlikely, is that the large difference in migration may be attrib ted to differential uptake of SDS under nonreducing and reducin conditions (5). Multisquamatin, on the other hand, has a '$ molecular mass of 6,400 Da under nonreducing conditions and 5,700 Da under reducing conditions. Echistatin, the pl.AI purified from the venom of Echis carinatus (Mr=5.4 kDa) (S), exhibits a similar differential migration pattern to that of multisquamatin under reducing and nonreducing SDS-PAGE.
This pattern in SDS-PAGE migration could be attributed to differential detergent binding based on structural differences under reducing and nonreducing conditions. The symbols are the same as for contortrostatin.
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FIG. 4.
SDS-PAGE
Varying concentrations of multisquamatin were preincubated with PRP as for contortrostatin. Multisquamatin has an IC50 of 0.55 pg/ml, 1.6 pg/ml and 1.9 pg/ml for human, canine and rabbit platelet aggregation, respectively. Each point represents the average of three determinations.
Determination of GPIIb/IIIa specific bindins of pl.AIs usins the monoclonal antibodv.7E3: The murine monoclonal antibody, 7E3, is a potent inhibitor of human and canine platelet aggregation (11).
To determine if contortrostatin and multisquamatin inhibit platelet aggregation by binding to GPIIb/IIIa, we employed competitive binding studies using 7E3. These studies demonstrated specific platelet GPIIb/IIIa receptor binding for the two pl.AIs with both human and canine platelets (Fig. 6) .
The concentration of contortrostatin to inhibit 50% of 7E3 binding to human GPIIb/IIIa (IC50) is 0.4 pg/ml. Multisquamatin has an IC5 for human GPIIb/IIIa of 0.018 pg/ml.
:,":Ib;;?n for contortros atin P and multisquamatin for canine a is 0.24 yg/ml and 0.36 pg/ml, respectively. These studies indicate that both contortrostatin and multisquamatin inhibit platelet aggregation by binding to GPIIb/IIIa. for contortrostatin displacement of 7E3 is 0.25 pg/m and for multisquamatin it is 0.36 pg/ml. Refer to Materials and Methods for a detailed description. Each point represents the average of at least three determinations.
DISCUSSION
Recently platelet aggregation inhibitors have been purified from venoms of snakes of the Crotalidae and Viperidea families (4-10). The first pl.AI to be reported was trigramin from Trimeresurus gramineus venom (4). This pl.AI was shown to bind to the GPIIb/IIIa complex on the platelet surface (4). All pl.AIs purified thus far, with the exception of barbourin (8), possess the RGD sequence. This sequence motif has been implicated as being involved in the inhibition of integrin mediated interactions (1) .
Therefore, a number of investigators have examined the efficacy of linear and cyclic RGD peptides (15, 16) or cyclic KGD peptides (17) as antiplatelet agents.
However, there appears to be increasing evidence that pl.AIs may have unique surface geometry which facilitates interactions with integrins by mechanisms other than those solely based on the RGD site. Recently it has been reported Vol. 73, No. 1
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that some snake venom metalloproteinases, which have no structural resemblance to mammalian matrix-degrading metalloproteinases, contain a domain which bears a striking resemblance to the pl.AI sequence (18-21). Although the pl.AI domain is devoid of the RGD sequence in at least one of the metalloproteinases (18), the proteinase is a potent inhibitor of ADP-and collagen-induced platelet aggregation.
Furthermore, the finding that a mutated, chemically synthesized pl.AI derivative of echistatin (alanine substituted for arginine in the RGD sequence) still possessed some biological activity (22), suggests that other regions in the protein may be involved in binding and that there may be some flexibilty in the RGD binding site.
The synthetic RGD peptides, due to their small size, do not possess the molecular topography of the pl.AIs and, therefore, cannot interact with the multiplicity of mechanisms used by pl.AIs. The partial amino acid sequence of contortrostatin shows significant identity with applaggin (6).
However, there appears to be an interesting difference in that the sequence for contortrostatin begins nine amino acid residues downstream from the applaggin start site (unpublished results 
